Adamis Pharmaceuticals Co. (NASDAQ:ADMP) shares traded up 7.2% on Monday . The company traded as high as $4.70 and last traded at $4.50. 58,823 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 662,786 shares. The stock had previously closed at $4.85.
A number of analysts have issued reports on the company. HC Wainwright assumed coverage on Adamis Pharmaceuticals in a report on Monday, April 23rd. They issued a “buy” rating and a $7.00 target price on the stock. Maxim Group set a $5.00 target price on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 19th. Zacks Investment Research lowered Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 16th. ValuEngine raised Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, B. Riley reaffirmed a “buy” rating on shares of Adamis Pharmaceuticals in a report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $7.88.
The firm has a market cap of $156.93 million, a PE ratio of -4.96 and a beta of 0.36. The company has a quick ratio of 1.57, a current ratio of 1.88 and a debt-to-equity ratio of 0.07.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.06). The business had revenue of $3.18 million during the quarter, compared to analyst estimates of $3.34 million. Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%. equities research analysts predict that Adamis Pharmaceuticals Co. will post -0.74 earnings per share for the current year.
Several large investors have recently made changes to their positions in the company. B. Riley Financial Inc. acquired a new stake in shares of Adamis Pharmaceuticals during the 4th quarter worth approximately $1,022,000. Northern Trust Corp grew its holdings in shares of Adamis Pharmaceuticals by 50.7% during the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock worth $489,000 after purchasing an additional 46,924 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Adamis Pharmaceuticals during the 4th quarter worth approximately $442,000. Dimensional Fund Advisors LP acquired a new stake in shares of Adamis Pharmaceuticals during the 1st quarter worth approximately $244,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Adamis Pharmaceuticals by 1,050.3% during the 4th quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock worth $124,000 after purchasing an additional 25,732 shares in the last quarter. 10.47% of the stock is currently owned by institutional investors.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.